HC Wainwright Estimates Disc Medicine Q1 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Disc Medicine in a note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao anticipates that the company will post earnings per share of ($1.53) for the quarter. HC Wainwright currently has a “Buy” rating and a $127.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.23) per share.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.10.

A number of other research analysts also recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating and issued a $149.00 price target on shares of Disc Medicine in a report on Wednesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Thursday, October 15th. Wells Fargo & Company lifted their target price on shares of Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. Cantor Fitzgerald lifted their target price on shares of Disc Medicine from $125.00 to $170.00 and gave the company an “overweight” rating in a report on Monday, October 19th. Finally, Wedbush boosted their target price on shares of Disc Medicine from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $124.18.

Disc Medicine Stock Up 4.2%

Disc Medicine stock opened at $84.64 on Monday. The business’s 50-day moving average price is $71.35 and its 200 day moving average price is $71.00. The company has a quick ratio of 24.14, a current ratio of 20.30 and a debt-to-equity ratio of 0.10. The firm has a market cap of $324.17 million, a price-to-earnings ratio of -13.35 and a beta of 0.96. Disc Medicine has a 52 week low of $40.00 and a 52 week high of $99.50.

Institutional Trading of Disc Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in IRON. State of Wyoming purchased a new position in shares of Disc Medicine during the 2nd quarter valued at approximately $25,000. Allworth Financial LP acquired a new stake in Disc Medicine in the 2nd quarter valued at $46,000. Sterling Capital Management LLC increased its holdings in Disc Medicine by 842.4% in the 3rd quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock worth $61,000 after acquiring an additional 834 shares in the last quarter. Nykredit A S purchased a new stake in Disc Medicine in the 2nd quarter worth $103,000. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in Disc Medicine during the third quarter worth $119,000. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Disc Medicine

In related news, Director Kevin Bitterman sold 49,164 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $80.17, for a total value of $3,941,477.88. Following the completion of the transaction, the director owned 13,499 shares of the company’s stock, valued at approximately $1,082,214.83. This represents a 78.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John D. Quisel sold 33,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $79.15, for a total value of $2,611,950.00. Following the transaction, the chief executive officer owned 226,064 shares in the company, valued at $17,892,965.60. This represents a 12.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 167,242 shares of company stock worth $13,124,591 in the last 90 days. Corporate insiders own 3.76% of the company’s stock.

Key Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $127 price target. It raised its 2026–2028 EPS forecasts, including improving its FY2027 estimate from a loss of $6.47 per share to a loss of $5.56. MarketBeat analyst estimates
• Positive Sentiment: A separate report cited a consensus price target of $124.18, reflecting analysts’ potential valuation upside. Disc Medicine consensus target price article
• Neutral Sentiment: A short-interest report listed 0 shares short and a 0.0-day short-interest ratio. Its wording also describes a “significant increase,” which conflicts with the zero figure, so it offers little clear signal for the stock.
• Negative Sentiment: HC Wainwright cut its FY2029 EPS forecast from $1.03 to $0.78 and its FY2030 forecast from $7.34 to $6.23, tempering the more favorable revisions for nearer years. MarketBeat analyst estimates

About Disc Medicine

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.